BACKGROUND: To examine whether androgen receptor (AR) CAG repeat length was associated with the risk of incident benign prostatic hyperplasia (BPH). METHODS: A nested case-control study of 416 BPH cases and 527 controls drawn from Prostate Cancer Prevention Trial placebo-arm participants who were free of BPH at baseline. BPH was assessed over 7 years and was defined as receipt of medical or surgical treatment, two scores > 14 on the International Prostate Symptom Score (IPSS), or two increases in IPSS > or = 5 with at least one score > or = 12. RESULTS: Compared to men with AR repeat length < or = 19, the covariate-adjusted odds ratios [95% CI] were 1.07 [0.73, 1.57] and 0.90 [0.55, 1.45]) for repeat length 20-24 and > or =25, respectively. There was a weak association of AR repeat length with baseline serum testosterone (T) (Spearman r = 0.09, p < 0.02); however, control for or stratification by T did not change study results. Further, results did not differ when stratified by body mass index or baseline concentration of 3alpha-diol glucoronide, and were similar for all BPH definitions. CONCLUSIONS: There were no associations of AR CAG repeat length and BPH risk. Knowledge of AR CAG repeat length provides no clinical useful information for the prevention of symptomatic BPH.
BACKGROUND: To examine whether androgen receptor (AR) CAG repeat length was associated with the risk of incident benign prostatic hyperplasia (BPH). METHODS: A nested case-control study of 416 BPH cases and 527 controls drawn from Prostate Cancer Prevention Trial placebo-arm participants who were free of BPH at baseline. BPH was assessed over 7 years and was defined as receipt of medical or surgical treatment, two scores > 14 on the International Prostate Symptom Score (IPSS), or two increases in IPSS > or = 5 with at least one score > or = 12. RESULTS: Compared to men with AR repeat length < or = 19, the covariate-adjusted odds ratios [95% CI] were 1.07 [0.73, 1.57] and 0.90 [0.55, 1.45]) for repeat length 20-24 and > or =25, respectively. There was a weak association of AR repeat length with baseline serum testosterone (T) (Spearman r = 0.09, p < 0.02); however, control for or stratification by T did not change study results. Further, results did not differ when stratified by body mass index or baseline concentration of 3alpha-diol glucoronide, and were similar for all BPH definitions. CONCLUSIONS: There were no associations of AR CAG repeat length and BPH risk. Knowledge of AR CAG repeat length provides no clinical useful information for the prevention of symptomatic BPH.
Authors: E Giovannucci; E A Platz; M J Stampfer; A Chan; K Krithivas; I Kawachi; W C Willett; P W Kantoff Journal: Urology Date: 1999-01 Impact factor: 2.649
Authors: Sean Walsh; Joseph M Zmuda; Jane A Cauley; Patrick R Shea; E Jeffrey Metter; Ben F Hurley; Robert E Ferrell; Stephen M Roth Journal: J Appl Physiol (1985) Date: 2004-09-17
Authors: Outi Renko; Eeva-Riitta Savolainen; Ildikó Loikkanen; Timo K Paavonen; Markku H Vaarala Journal: DNA Cell Biol Date: 2008-02 Impact factor: 3.311
Authors: Rosebud O Roberts; Erik J Bergstralh; Julie M Cunningham; Scott J Hebbring; Stephen N Thibodeau; Michael M Lieber; Steven J Jacobsen Journal: Am J Epidemiol Date: 2004-02-01 Impact factor: 4.897
Authors: Jeannette M Schenk; Rachel Hunter-Merrill; Yingye Zheng; Ruth Etzioni; Roman Gulati; Catherine Tangen; Ian M Thompson; Alan R Kristal Journal: Am J Epidemiol Date: 2013-06-28 Impact factor: 4.897
Authors: Rufus Cartwright; Altaf Mangera; Kari A O Tikkinen; Prabhakar Rajan; Jori Pesonen; Anna C Kirby; Ganesh Thiagamoorthy; Chris Ambrose; Juan Gonzalez-Maffe; Phillip R Bennett; Tom Palmer; Andrew Walley; Marjo-Riitta Järvelin; Vik Khullar; Chris Chapple Journal: Eur Urol Date: 2014-01-22 Impact factor: 20.096
Authors: S Madjunkova; A Eftimov; V Georgiev; D Petrovski; Aj Dimovski; D Plaseska-Karanfilska Journal: Balkan J Med Genet Date: 2012-06 Impact factor: 0.519